CURRICULUM VITAE

A. PERSONAL DETAILS
a. Name: DR. AMIT JOSHI
b. Nationality: Indian
c. Date of birth: 30/11/1974
d. Permanent Address:C/o Dr. Amit Joshi
Flat No. 207. Vishwakarma Towers, Aruna Asif Ali
CHS, Plot No. 4, Sector 21, Kharghar, 410210,
Navi Mumbai, Maharashtra
e. Registration No: MP:2200
h. E mail-id:dramitjoshi74@gmail.com

i. Phone number: 09769331525

B. EDUCATIONAL QUALIFICATIONN
a. MBBS SS Medical College Rewa ( MP) 1997
b. MD (Medicine ): SS Medical College Rewa ( MP) 2002
c. DM (Medical Oncology): Gujarat Cancer Research Institute
Ahmedabad (2007)
C. PROFESSIONAL EXPERIENCE

1. Assistant Professor:Dept. Of Medical Oncology Tata Memorial Hospital (2008

-09)
2. Associate Professor:Dept. Of Medical Oncology Tata Memorial Hospital
(2009-2011)
3. Professor: Since 2011 till date.

D. Area Of Interest: Genitourinary, Thoracie and Head and Neck Oncology

E. List your most Current Clinical Research below:

Type of Trial Phase: Completed
Therapeutic Area: Ongoing
Comparative study of QOL of patients| Observational
on Pemetrexed versus Erlotinib in
Maintenance therapy for Advanced
NSCLC (Other than Squamous Cell
Carcinoma)
An Observational Study to evaluate Observational
factors predicting survival in patients
of NSCLC with compromised PS.

Germ Cell tumor outcome and long Observational

tem follow up study (GTOF)

Prospective observatioal study of Observational

thrombocmbolie events in patients of
advanced stage non small eell lung
cancer(NSCLC)Ireated with platinum
bascd chemotherapy
Retrospeetive analy sis of efticacy and Retrospective
tonicity protile of tirst line Tyrosine
kinase inhibitors in the treatnent of
metastatie Renal cell carcinoma-
Expericnce from a Tertiary Relerral
centre.
Retrospective analysis of palliative Retrospective
metronomie chemotherapy in Head
and Neck cancers.
Protocol no. NOPRODPCR4001- A Observational
multicenter. prospective, longitudinal
registry otf patients wvith prostate
cancerin Asia.
Retrospective audit of using Retrospective
Abiraterone acetate in patients of
castrate resistant prostate cancer
(CRPC) at Tata Memorial Centre.
A randomized trial to compare International
gefitinib plus chemotherapy vs
chemotherapy alone in EGFR positive
and T790M mutation negative
advanced Non-small cell lung cancer
patients after progression on first line
gefitinib.
A prospective study to evaluate the Observational
Adverse Drug Reactions and to assess
quality of life in prostate cancer
patients receiving docetaxel in Tata
Memorial Centre.
A study of factors associated with Observational
delay presentation of patients with
ed
Testicular Germ Cell Tumors for
at Tata
seeking specialized care

Memorial Hospital. (DelP-GCT)

A Prospective. observational study to Observational
translate and validate, a patient
reported outcome (PRO) measure

COST FACIT (Version 2)

Marathi.
questionnaire into Hindi and
A Prospective, Observational study to Observational
Compare (Quality of Life and side
elfects in patients undergoing Medical
ersus Surgical Castration in
Metasttic Carcinoma of Prostate at
Tata Memorial Hospital
Kidney Cancer Regrry Observational
 F. PUBLICATIONS JOURNAL PUBLICATIONS:

1. A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-

resistant prostate caneer
Joshi Amit, Shrirangwar Sameer, Noronha Vanita, Sable Nilesh. Agarwal Archi, Popat Palak,
Atanu. Prabhash Kumar. SAJC Year: 2020 Volume: 9 | Issue Number: |
Bhattacharjee
Page: 23-26

in
2. Rajendra A. Noronha V. Joshi A, Patil VM, Menon N, Prabhash K. Palliative chemotherapy
head and neck eancer: balancing between benetficial and adverse effects. Expert Rev
Anticancer Ther. 2020 Jan 3:1-13. doi: 10.1080/14737140.2020.1708197. [Epub ahead of
print] PubMed PMID: 31899993.

3. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Prabhash K. Reply to T.Tanaka et al

and F. Liang. J Clin Oncol. 2020 Jan 2:JCO1902974. doi: 10.1200/JCO. 19.02974. [Epub
ahead of print] PubMed PMID: 31895609.

4. Talreja VT, Noronha V, Joshi A, Patil V, Mahajan A. Prabhash K. Use of lorlatinib

subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer:

Indian experience. South Asian J Cancer. 2019 Oct-Dec:8(4):211. doi:

10.4103/sajc.saje_169_19. PubMed PMID: 31807477; PubMed Central PMCID:
PMC6852628.
5. Basu S. Parghane RV, Suman S, Joshi A, Prabhash K, Bakshi G, Banerjee S.Towards
personalizing treatment strategies in mCRPC: can dual-tracer PET-CTprovide insights into
tumor biology, guide the optimal treatment sequence, andindividualize decision-making
(between chemotherapy, second-generationanti-androgens and PSMA-directed radioligand
therapy) early in the diseasecourse? Eur J Nucl Med Mol Imaging. 2019 Nov 27. doi:
10.1007/s00259-019-04616-w.[Epub ahead of print] PubMed PMID: 31776630.

Thiagarajan s. Dhar H, Bhattacharjee A, Fatehi KS. Shah SB. Chaukar D, NairD, Deshmukh
A. Prabhash K. Joshi A, Patil V, Noronha V, Laskar SG, Cruz AKD.Patterns of failure and
outcomes in cT4 Oral squamous cell carcinoma (OSCC)undergoing upfront surgery in
comparison to Neo-Adjuvant Chemotherapy (NACT)followed by surgery: A Matched Pair
analysis. Oral Oncol. 2019 Nov 15;100:104455.doi: 10. 1016/.oraloncology.2019.104455.
[Epub ahead of print] PubMed PMID:31739192.
7. Patil v. Joshi A. Noronha V. Agarwala V, Chougule A, Kanan S, BhattacharjeeA.
Chandrasekharan A. Pande N, Simha V, Goud S, More S, Kumar R, Mahajan A. JanuA.
Purandare N, Prabhash K. Randomized phase 3 open label study of quality oflife of patients on
Pemetrexed versus Erlotinib as maintenance therapy foradvanced non squamous non EGFR
mutated non-small cell lung cancer. Oncotarget.2019 Oct 29;10(59):6297-6307. doi:
10.18632/oncotarget.27214. eCollection 20190ct 29. PubMed PMID: 31695838: PubMed
Central PMCID: PMC6824869.

8. Sali AP, Menon S. Prakash G, Murthy V. Bakshi G, Mahantshetty U, Joshi A,Desai SB.
Histopathological risk seoring system as a tool for predicting lymphnodal metastasis in penile
squamous cell carcinoma. Pathology. 2019Dec:1(7):696-704. doi:
10.1016/j.pathol.2019.08.003. Epub 2019 Oct 18. PubMedPMID: 31635947.
9Suman S. Parghane RV. Joshi A, Prabhashh K. Bakshi G. Talole S, Banerjee S,Basu S.
herapeutic etticacy. prognostie variables and clinical outcome of(1 77)Lu-PSMA-617 PRLT
n progressive mCRPC following multiple lines of treatment:prognostic implications of high
uptake on dual traeer PET-CT vis-d-visGleason score in such cohort. Br J Radiol. 2019
Dec:92(1104):20190380. doi:10.1259/bjr.20190380. Epub 2019 Nov . PubMed PMID:
31600089: PubMed CentralPMCID: PMC6913363

10. Patil VM. Noronha V, Joshi

A, DhumalS, Mahimkar M, Bhattacharjee A, Gota V, Pandey M,
Menon N. Mahajan A, Sable N, Kumar S, Nawale K, Mukadam S, Solanki B,Das S, Simha V,
Abraham G. Chandrasekharan A, Talreja V, DSouza H, Srinivas S,Kashyap L, Banavali S,
Prabhash K. Phase II Study of Palliative TripleMetronomic Chemotherapy in Platinum-
Refractory/Early-Failure Oral Cancer. J Clin Oncol. 2019 Nov 10;37(32):3032-3041. doi:
10.1200/JCO.19.01076. Epub 2019 Sep 20.PubMed PMID: 31539316.
11. Natarajan A. Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, Shah
S,Puranik A,
Rangarajan V. Initial experience of Ga-68 prostate-specific membraneantigen positron
emission tomography/computed mography imaging in evaluation ofbiochemical recurrence
in prostate cancer patients. World J Nucl Med. 2019Jul-Sep;18(3):244-250. doi:
10.4103/wjnm.WJNM_47_ 18. PubMed PMID: 31516367;PubMed Central PMCID:
PMC6714163.

12. Mathew B. Agrawal A, Purandare NC, Ramadwar

M, Menon S, Bakshi G, Joshi A,Puranik A.
Shah S. Rangarajan V. Incidental Detection of
Pleomorphic Sarcoma on68Ga-PSMA PET/CT
in a Patient With Prostate Cancer. Clin Nucl Med.
2020Feb;45(2):e120-e121. doi:
10.1097/RLU.0000000000002760. PubMed PMID: 314903 15.
13. Dhumal S. Chandrasekharan A, Patil V, Noronha V, Joshi A, Puranik
Prabhash K. A,Rangarajan V,
Neoadjuvant chemotherapy in technically unresectableadenocarcinoma of parotid.
South Asian J Cancer. 2019 Jul-Sep;8(3):185.
31489295; PubMed Central PMCID: PMC6699227.
doi:10.4103/sajc.saje_87_19. PubMed PMID:

14. Patil VM. Joshi A, Noronha V, Talreja V, Simha V, Dhumal S, Bandekar

B,Chandrasekharan
A. Prabhash K. Palliative chemotherapy in carcinoma
nasopharynx.
South Asian J Cancer.
2019 Jul-Sep:8(3):173-177. doi: 10.4103/sajc.sajc_230_18.PubMed PMID: 31489292;
PubMed Central PMCID: PMC6699237
15. Talreja VT. Noronha V, Joshi A, Patil V, Mahajan A, Prabhash K.
Anexceptional response to
nivolumab in relapsed and refractory
malignantmesothelioma. South Asian J Cancer. 2019 Jul-
Sep:8(3):159. doi:10.4103/saje.saje_18_19. PubMed PMID: 31489287: PubMed Central
PMCID: PMC6699239.

16. Noronha V. Patil VM, Joshi A, Menon N.

Chougule A, Mahajan A, Janu A,Purandare N,
Kumar R, More S. Goud S, Kadam N, Daware N,
Bhattacharjee A, Shah S,Yadav A, Trivedi
V, Behel V. Dutt A. Banavali SD, Prabhash K. Gefitinib
VersusGefitinib Plus Pemetrexed and
Carboplatin Chemotherapy in EGFR-Mutated LungCancer. J Clin Oncol. 2020 Jan
10:3882):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. PubMed PMID:
31411950.

17. Patil VM, Noronha V. Joshi A, Agarwal J, Ghosh-Laskar S. Budrukkar A, Murthy V,

T. Mahimkar M. Juvekar S, Arya S, Gupta
Mahajan A, Agarwal A. Purandare N,Rangarajan V,
 Balaji A. Chaudhari SV, Banavali S, Kannan S, Bhatlacharjee A.D'Cruz. AK, Chaturvedi P, Pai
P's. Chaukar D. Pantvaidya G. Nair D. Nair S.Deshmukh A. Thiagarajan S, Mathrudev
Manirekar A. Dhumal S. Maske K. Bhelekar AS. Nawale K. Chandrasekharan A, Pande N.
Goel A. Talreja V. Simha V. Srinivas S,Swami R, Vallathol DH, Dsouza H, Shrirangwar s
Turkar S. Abraham G. 1hanky AH.Patel U, Pandey MK. Prabhash K. A randomized phase
trial comparing nimotuzumab plus cisplatin ehemo radiotherapy versus cisplatin chemo
radiotherapy alone inlocally advanced head and neck cancer. Cancer. 2019 SepP
15:125(18):3184-3197.doi: 10.1002/cner.32179. Epub 2019 May 31. PubMed PMID:
31150120

I8. Patil V. Noronha V. Joshi A. Chougule A, Kannan S, Bhattacharjee A, Goud S,More S,

Chandrasekharan A. Menon N. Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S,
Zawar A. Khaddar S. Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V,Behel V, Mahajan
A. Janu A. Purandare N, Prabhash K. Phase llI Non-inferiorityStudy Evaluating Efficacy and
Safety of Low Dose Gemcitabine Compared to StandardDose Gemcitabine With Platinum in
Advanced Squamous Lung Cancer.EClinicalMedicine. 2019 Apr 9;9:19-25. doi
10.1016j.eclinm.2019.03.011.eCollection 2019 Mar. PubMed PMID: 31143878; PubMed
Central PMCID: PMC6510888.

19. Prakash G. Pal M, Odaiyappan K. Shinde R, Mishra J, Jalde D, Rajkumar B.Prabhash K, Joshi
A. Noronha V. Murthy V. Krishnatry R, Desai S. Menon S, SableN, Popat P, Rangarajan V,
Agrawal A. Bakshi G. Bladder cancer demographics andoutcome data from 2013 at a tertiary
cancer hospital in India. Indian J Cancer.2019 Jan-Mar:56(1):54-58. doi:
104103 ijc.IJC_351_18. PubMed PMID: 30950446.

20. Joshi A. Pande N, Noronha V, Patil V, Kumar R, Chougule A, Trivedi V, Janu A,Mahajan A,
Prabhash K. ROSI mutation non-small cell lung cancer-access to optimaltreatment and
outcomes. Ecancermedicalscience. 2019 Jan 29;13:900. doi:10.3332/ecancer.2019.900.
eCollection 2019. PubMed PMID: 30915158; PubMed CentralPMCID: PMC6390829.

21. Kate S. Chougule A. Joshi A, Noronha V, Patil V, Dusane R, Solanki L.TiwrekarP, Trivedi
V. Prabhash K. Outcome of
uncommon EGFR mutation positivenewly diagnosed
advanced
non-small cell lung cancer patients: a single centerretrospective analysis. Lung Cancer
(Auckl). 2019 Jan 29;10:1-10. doi:10.2147/LCTT.S181406. eCollection 2019. PubMed PMID:
30774491: PubMed CentralPMCID: PMC6357894.

22. Joshi A. Kate S. Noronha V, Patil V, Trivedi V, Goud

S, More S, Bhairva S,Prabhash K.
Thromboembolic events in patients with advanced stage non-small cell
w ith
lung cancer treated
platinum-based chemotherapy: a prospective observationalstudy. Ecancermedicalscience.
2018 Oct 9; 12:876. doi: 10.3332/ecancer.2018.876.eCollection 2018. PubMed PMID:
30483356: PubMed Central PMCID: PMC6214681.

23. Pahuja KB. Nguyen TT, Jaiswal BS,

Prabhash K, Thaker TM., Senger K, Chaudhuri S,
NM. Antony A. Phalke S,
Kumar P, Mravic M, Stawiski EW, Kljavin
Vargas D,Durinck S, Gupta R,
Khanna-Gupta A. Trabucco SE. Sokol ES, Hartmaier RJ, Singh
Dutt A. Patil V, Joshi A. Noronha V, Ziai A.Chougule A, Trivedi V.
J, Banavali SD, Ramprasad V, DeGrado WF, Bueno
R. Jura N, Seshagiri S. Actionable
ActivatingOncogenic ERBB2/HER2 Transmembrane and
Juxtamembrane Domain Mutations. CancerCell. 2018 Nov
12:34(5):792-806.e5.
10.1016/jccell.2018.09.010. Epub 20180ct 25. PubMed PMID: 30449325; PubMed Central doi:
PMCID: PMC6248889.
24. Patil V. Joshi A. Noronha V. Bhattacharjee A, Dhumal S, Chandrakanth MV,Karpe A. Talreja
v. Chandrasekharan A. Turkar S. Pande N, Ramaswamy A, PrabhashK. Quality of life and
quality-adjusted time without toxicity in palliativelytreated head-and-neck cancer patients.
South AsianJ Cancer. 20180ct-Dec:7(4):249-253. doi: 10.4103/saje.sajc_233_17. PubMed
PMID: 30430094:PubMed Central PMCID: PMC6190391.

25. Agarw ala V. Ramaswamy A. Joslhi A, Patil VM, Noronha V, Menon S, Popat BP,Sable N,
Prabhash K. Treatment outcomes of metastatic nonclear cell renal cellcarcinoma: A single
institution retrospective analysis. South Asian J Cancer.2018 Oct-Dec:7(4):226-230. doi:
10.4103/sajc.saje_22_18. PubMed PMID: 30430089:PubMed Central PMCID: PMC6190394.

26. Basu S. Parghane RV. Joshi A, Prabhash K, Banerjee S. The rationality ofcombining second-
generation antiandrogens with 177Lu-PSMA or its alpha-emittingcongeners for better and
durable results: will this dominate the therapeuticlandscape and be an upfront consideration in
metastatic castration-resistantprostate cancer in the coming years? Nucl Med Commun. 2018
Dec:39(12): 1061-1063. doi: 10.1097/MNM.0000000000000932. PubMed PMID: 30339554.

27. Balaji SA, Shanmugam A, Chougule A, Sridharan S, Prabhash K, Arya A, Chaubey A,

Hariharan A. Kolekar P, Sen M, Ravichandran A, Katragadda S, Sankaran S,Bhargava S.
Kulkarni P. Rao S,. Sunkavalli C, Banavali S, Joshi A, Noronha V, DuttA, Bahadur U,
Hariharan R. Veeramachaneni V, Gupta V. Analysis of solid tumormutation profiles in liquid
biopsy. Cancer Med. 2018 Nov:7(11):5439-5447. doi:10.1002/cam4.1791. Epub 2018 Sep 27.
PubMed PMID: 30264478; PubMed Central PMCID:PMC6246960.

28. Patil V. Noronha V. Joshi A, Deodhar J, Goswami S, Chakraborty S, RamaswamyA, Dhumal

S. M VC. Karpe A. Pande N, Talreja V, Chandrasekharan A, Turkar S,Prabhash K. Distress
Management in Patients With Head and Neck Cancer BeforeStart of Palliative Chemotherapy:
A Practical Approach. J Glob Oncol. 2018Sep:4:1-10. doi: 10.1200/JGO. 17.00044. PubMed
PMID: 30241232: PubMed CentralPMCID: PMC6223409.

29. Doshi KH. Shriyan B, Nookala MK, Kannan S, Joshi A, Noronha V, Gota V,Prabhash K
Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer
treated with pemetrexed-platinum doublet chemotherapy. J Cancer Res Ther. 2018 Jul-
Sep:14(5):1049-1053. doi:10.4103/0973-1482.187296.PubMed PMID: 30197346.
30. Dhumal SB. Patil VM. Joshi A, Noronha V, Chandrasekharan A, Pai P, Prabhash K. Long
term survival outcomes of technically unresectable carcinoma maxilla postinduction
chemotherapy. South Asian Cancer. 2018 Jul-Sep:7(3):213-214.
doi:10.4103/saje.sajc_165_18. PubMed PMID: 30112346: PubMed Central
PMCID:PMC6069330.

31. Dhumal SB. Patil VM, Joshi A, Noronha V, Chandrasekharan A, Pai P, Prabhash K. Long
term survival outcomes of technically unresectable carcinoma maxilla postinduction
chemotherapy. South Asian J Cancer. 2018 Jul-Sep:7(3):213-214.
doi: 10.4103/saje.sajc_165_18. PubMed PMID: 30112346: PubMed Central
PMCID:PMC6069330.

32. Dhumal SB. Patil VM. Joshi A, Noronha V, Chandrasekharan A. Pai P, Prabhash K. Long
term survival outcomes of technically unresectable carcinoma maxillapostinduction
 chemotherapy. South Asian J Cancer 2018 Jul-Sep:7(3):213-214.
Central
doi:10.4103/sajc.sajc_165_18. PubMed PMID 30112346: PubMed
PMCID:PMC6069330.

33. Prabhash K. Parikh PM, Rajappa SJ, Noronha V, Joshi A. Aggarwal S, BondardeS. Patil S
Desai C. Dattatreya PS. Naik R. Anand S. Chacko RT. Biswas G. SahooTP, Dabkara D. Pati
V. Chandrakant MV, Das PK. Vaid AK. Doval DC. Pattens ofepidermal growth factor
receptor testing across 111 tertiary care centers inIndia: Result of a questionnaire-based
survey. South Asian J Cancer. 2018Jul-Sep:703):203-206. doi: 10.4103/sajc.saje_30_18.
PubMed PMID: 30112342: PubMedCentral PMCID: PMC6069335.

34. Majumdar S, Noronha V, Joshi A, Patil V, Kumar R. Trivedi V. Prabhash K.Sequential

treatment with alectinib in crizotinib-resistant non-smal-cell lungcancer. South Asian
Cancer. 2018 Jul-Sep;7(3):194. doi:10.4103/sajc.sajc_199_18. PubMed PMID: 30112339;
PubMed Central PMCID:PMC6069325.

35. Zanwar S, Noronha V, Joshi A. Patil VM, Kaushal R. Chougule A. Janu A.Mahajan A.
that
Kapoor A, Prabhash K. Efficacy of crizotinib in ALK mutant non-smallcell lung cancers
are positive by IHC but negative by FISH compared to FlSH positive cases. lIndian J Cancer.
2017 Oct-Dec;54(4):678-680. doi:10.4103/ijc.1JC_532_16. PubMed PMID: 30082557.

36. Joshi A, Anand A, Prabhash K, Noronha V, Shrirangwar S. Bakshi G. Pal M.Murthy V.

Krishnatry R, Desai S, Menon S. Patil D. Kulkarni S. Sable N. Popat P. Agrawal A.

2013 at a
Rangarajan V, Prakash G. Kidney cancer demographics and outcome datafrom
in India. Indian J Cancer. 20170ct-Dec:54(4):601-604. doi:
tertiary cancer hospital
10.4103/ijc.IJC_644_17. PubMed PMID: 30082542.

37. Parchur AK, Sharma G, Jagtap JM, Gogineni VR, LaViolette PS, Flister MJ.White SB. Joshi
A. Vascular Interventional Radiology-Guided Photothermal Therapy of Colorectal Cancer
Liver Metastasis with Theranostic Gold Nanorods. ACS Nano.2018 Jul 24:12(7):6597-6611.
doi: 10.1021/acsnano.8b0 1424. Epub 2018 Jul 6.PubMed PMID: 29969226.

38. Joshi A, Sahu A, Noronha V, Patil V, Prabhash K. Metastatic Renal CellCancer-Systemic

Therapy. Indian J Surg Oncol. 2018 Mar:9(1):97-104. doi:10. 1007/s13 193-018-0721-2. Epub
2018 Jan 29. PubMed PMID: 29563746: PubMedCentral PMCID: PMC5856703.

A. Gupta S. Bhattacharjee A, Bonda

39. Joshi A, Patil VM, Noronha V, Ramaswamy
A,Chandrakanth MV, Ostwal V, Khattry N, Banavali S, Prabhash K. EMERALD: Emergency
visit audit of patients treated under medical oncology in a tertiary cancercenter: Logical steps

decrease the burden. South Asian J Cancer. 2017Oct-Dec:6(4): 186-189. doi

to
PubMed PMID: 29404304:PubMed Central PMCID
10.4103/saje.saje_128_17.
PMC5763636.

A. Prabhash K.Osimertinib in
40. Noronha V, Majumdar S, Joshi A, Patil V, Trivedi V, Chougule
nonsmall cell lungcancer. South Asian J
Indian patients with T790M-positive advanced
PubMed PMID: 29404287:
Cancer. 2017 Oct-Dec:6(4): 143. doi:10.4103/sajc.sajc_202_17.
PubMed Central PMCID:PMC5763619.

R.
Routhu T, Mandloi N, Noronha V, Joshi A. Dutt A,Gupta
41. Veldore VH. Choughule A. cell-free DNA testing in clinical
Vedam R, Prabhash K. Validation of liquid biopsy: plasma
 managenent of advanced non-small cell lung cancer. LungCancer (Auckl). 2018 Jan 3;9:1-11.
doi: 10.2147/LCTT.S147841. eCollection 2018.PubMed PMID:
29379323: PubMed Central
PMCID: PMC5757203.

42. Joshi A. Patil V, Noronha V,

Chougule A, Bhattacharjee A, Kumar R, Goud S,More S,
Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A. Talreja V,Mahajan A. Janu
A. Purandare N, Prabhash K.
Efficacy of gefitinib in epidermalgrowth factor receptor-
activating mutation-positive nonsmall cell lung cancer:Does exon 19 deletion differ from exon
21 mutation?
Lung India. 2018Jan-Feb;35(1):27-30. doi: 10.4103/lungindia.lungindia_201_1 7.
PubMed PMID:29319030; PubMed Central PMCID:
PMC5760863.
43. Joshi A, Tandon N, Patil VM, Noronha V, Gupta S, Bhattacharjee A. Prabhash K.Agreement
analysis between three different short geriatric
screening scales inpatients undergoing
chemotherapy for solid tumors. J Cancer Res Ther. 20170ct-Dec:13(6):1023-1026. doi:
10.4103/0973-1482.179062. PubMed PMID: 29237969.
44. Agarwal JP, Chakraborty S, Laskar SG, Mummudi N. Patil VM. Prabhash K.Noronha V.
Purandare N, Joshi A, Tandon S, Arora J, Badhe R.
Prognostic value of a
functional score versus physician-reported KarnofskyPerformance Status patient-reported
Score in brain
metastases. Ecancermedicalscience. 2017 Nov10:11:779. doi: 10.3332/ecancer.2017.779.
eCollection 2017. PubMed PMID:29225686; PubMed Central PMCID: PMC5718029.

45. Joshi A, Patil V, Noronha V, Dhumal S, Pande N. Chandrasekharan A. Turkar

S.DSouza H.
Shrirangwar S, Mahajan A, Arya S, Juvekar S, BhattaCharjee A, Prabhash K. Results of a
phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus
Docetaxel as second line or above therapy in recurrent headand neck cancer. Oral Oncol. 2017
Dec:75:54-60. doi:10.1016/j.oraloncology.2017.10.018. Epub 2017 Nov 5. PubMed PMID:
29224823.

46. Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A. MurthyV, Gupta T.
D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N.Chandrasekharan A,
Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K.Bhelekar AS, Nawale K,
Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL.Prabhash K. Once-a-Week Versus
Once-Every-3-Weeks Cisplatin Chemoradiation forLocally Advanced Head and Neck Cancer:
A Phase III Randomized NoninferiorityTrial. J Clin Oncol. 2018 Apr 10:36(11):1064-1072.
doi: 10.1200/JCO.2017.74.9457.Epub 2017 Dec 8. PubMed PMID: 29220295.

47. Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A. Kumar R. Goud S. More S.
Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V,Mahajan A. Janu
A, Purandare N, Prabhash K. Efficacy of Second-LinePemetrexed-Carboplatin in EGFR-
Activating Mutation-Positive NSCLC: Does Exon 19Deletion Differ from Exon 21 Mutation?
Chemother Res Pract. 2017:2017:8196434doi: 10.1155/2017/8196434. Epub 2017 Oct 23.
PubMed PMID: 29201462; PubMedCentral PMCID: PMC5672602.

48. Ramaswamy A. Joshi A, Noronha V, Patil V, Sahu A. Manickam DR. Kothari R,Sable N. A
A, Menon S, Prabhash K. Poor Risk Advanced Renal Cell Carcinoma:Outcomes from a
Registry in a Tertiary Cancer Center. Indian J Med PaediatrOncol. 2017 Jul-Sep:38(3):311-
315. doi: 10.4103/ijmpo.ijmpo_154_16. PubMed PMID: 29200680: PubMed Central PMCID:
PMC5686973.
49. Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S,Goud S, Karpe
A, Janu A.
A. RamasSwamy A, Pande N. Chandrasekharan A, Goel A, Talreja V,Mahajan
Purandare N, Prabhash K. Impact of exon 19 versus exon 21EGFR-activating mutation on
outcomes with upfront pemetrexed-carboplatinchemotherapy. Ecancermedicalscience. 20
2017. PubMed PMID: 29104613;
Oct 24:11:776. doi:l0.3332/ecancer.2017.776. eCollection
PubMed CentralPMCID: PMC5659826.

Marfatia S.Punatar S, More

50. Noronha V, Joshi A. Patil VM. Banavali SD, Gupta S, Parikh PM,
intravenous to oral iron
S. Goud S, Nakti D, Prabhash K. Phase Il randomized trialcomparing
in patients with cancer-related irondeficiency anemia not on erythropoiesis
stimulating agents.
Asia Pac J ClinOneol. 2018 Apr;14(2):e129-e137. doi: 10.1111/ajco.12762. Epub 2017 Aug
28.PubMed PMID: 28849623.

S, Muddu V,
S1. Patil V, Noronha V, Joshi A, Parikh P, Bhattacharjee A, Chakraborty S,Jandyal
Banavali S, Prabhash K.
Ramaswamy A, Babu KG, Lokeshwar N, Hingmire S, GhadyalpatilN,
Survey of lmplementation of Antiemetic PrescriptionStandards in
Indian Oncology Practices
Antiemetic Clinical
and lts Adherence to the American Society of Clinical Oncology
Guideline. J Glob Oncol. 2016 Nov9;3(4):346-359. doi: 10.1200/JGO.2016.006023.
eCollection 2017 Aug. PubMed PMID: 28831443; PubMed Central PMCID: PMC5560456.

52. Deodhar JK, Noronha V, Muckaden MA, Atreya S, Joshi A, Tandon SP, Ghoshal A.Salins
NS, Patil VM, Prabhash K. A Study to Assess the Feasibility of IntroducingEarly Palliative
Care in Ambulatory Patients with Advanced Lung Cancer. Indian J Palliat Care. 2017 Jul-
Sep:23(3):261-267. doi: 10.4103/1JPC.1JPC_19_17. PubMedPMID: 28827928: PubMed
Central PMCID: PMC5545950.

53. Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, GoudS, More S.
Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V.Mahajan A. Janu
A, Purandare N, Prabhash K. Phase Ill study of gefitinib orpemetrexed with carboplatin in
EGFR-mutated advanced lung adenocarcinoma. ESMOOpen. 2017 Apr 27:2(1):e000168. doi:
10.1136/esmoopen-2017-000168. eCollection2017. PubMed PMID: 28761735; PubMed
Central PMCID: PMC5519810.

54. Bhatt VR, D'Souza SP, Smith LM, Cushman-Vokoun AM, Noronha V, Verma V, JoshiA,
Chougule A, Jambhekar N, Kessinger A, Marr A, Patil V, Banavali SD, Ganti AK, Prabhash
K. Epidermal Growth Factor Receptor Mutational Status and BrainMetastases in Non-Small-
Cell Lung Cancer. J Glob Oncol. 2016 Jul 20;3(3):208-217.doi: 10.1200/JGO.2016.003392.
eCollection 2017 Jun. PubMed PMID: 28717762; PubMedCentral PMCID: PMC5493216.

55. Noronha V, Choughule A, Palil VM, Joshi A, Kumar R, Susan Joy Philip D,Banavali S, Dutt
A. Prabhash K. Epidermal growth factor receptor exon 20 mutationin lung cancer: types,
incidence, clinical features and impact on treatment. OncoTargets Ther. 2017 Jun 9;10:2903-
2908. doi: 10.2147/OTT.S133245. eCollection2017. PubMed PMID: 28652772; PubMed
Central PMCID: PMC5476719.

S6. Chougule A, Patil VM. Noronha V, Joshi A. Turkkar S, Chandrasekharan A.Pande N.

Bagayatkar P. Prabhash K. Incidence and impact of Dihydropyrimidinedehydrogenase gene
mutation on neoadjuvant chemotherapy in head and neck cancers.Oral Oncol. 2017 Jul:70:73-
74. doi: 10.1016j.oraloncology.2017.05.006. Epub 2017May 22. PubMed PMID: 28545992,
57. Aggarwal J. Chakraborty S, Ghosh Laskar S, Patil VM, Prabhash K,Bhattacharya A, Noronha
V. Purandare NC, Joshi A, Mummudi N, Arora J, Badhe R.Reference Data for Standardized
Quality of Life Questionnaires in Indian Patientswith Brain Metastases from Non-small Cell
Lung Cancer: Results from a ProspectiveStudy. Cureus. 2017 Apr 10:9(4):el 149. doi:
10.7759/cureus.1 149. PubMed PMID:28497011: PubMed Central PMCID: PMC5425287

58. Patil VM, Noronha V, Joshi A, Ramaswamy A, Gupta S, Sahu A, Doshi V. GuptaT. Rath S.
Banavali S, Prabhash K. Adherence to and Implementation of ASCOAntiemetic Guidelines in
Routine Practice in a Tertiary Cancer Center in India. JOncol Pract. 2017 Jun;13(6):e574-e581.
doi: 10.1200/JOP.2016.019448. Epub 2017May 9. PubMed PMID: 28486012.

59. Joshi P, Joshi A, Norohna V, Chaturvedi P, Patil V. Agarwal JP, Juvekar S.Prabhash K. Role
of neoadjuvant chemotherapy in advanced carcinoma of thehypopharynx and larynx. South
Asian J Cancer. 2017 Jan-Mar;:6(1):15-19. doi:10.4103/2278-330x.202557. PubMed PMID:;
28413789; PubMed Central PMCID:PMC5379886.

60. Noronha V, Patil VM, Joshi A, Bhattacharjee A. Paul D. Dhumal S. Juvekar S, Arya S.
Prabhash K. A tertiary care experience with paclitaxel and cetuximab aspalliative
chemotherapy in platinum sensitive and nonsensitive in head and neckcancers. South Asian J
Cancer 2017 Jan-Mar:6(1):11-14. doi:10.4103/2278-330X.202558. PubMed PMID:
28413788; PubMed Central PMCID:PMC5379885.

61. Joshi A, Zanwar S, Noronha V, Patil VM. Chougule A, Kumar R, Janu A, MahajanA, Kapoor
A, Prabhash K. EGFR mutation in squamous cell carcinoma of the lung:does it carry the same
connotation as in adenocarcinomas? Onco Targets Ther. 2017Mar 28:10:1859-1863. doi
10.2147/0TT.S125397. eCollection 2017. PubMed PMID:28405 166: PubMed Central
PMCID: PMC5378442.

62. Kavathiya K, Gurjar M, Patil A, Naik M, Noronha V. Joshi A, Gota V, PrabhashK. A

Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in IndianAdult
Chemonaive Patients With Adenocarcinoma Stage Il1/IV Non-Small Cell LungCancer. Clin
Pharmacol Drug Dev. 2017 May:6(3):234-239. doi: 10.1002/cpdd.347.Epub 2017 Mar 29
PubMed PMID: 28371303.

63. Patil VM, Noronha V, Joshi A, Ramaswamy A. Dhumal S, Juvekar S. Arya S.Mahajan A.
Chaturvedi P, D'Cruz A, Bhattacharjee A. Prabhash K. Neoadjuvantchemotherapy in geriatric
head and neck cancers. Head Neck. 2017May:39(5):886-892. doi: 10.1002/hed.24694. Epub
2017 Mar 1. PubMed PMID: 28248432.

64. Lewis sC, D'eruz AK, Joshi A, Kumar R, Kane SV, Laskar SG. Thyroid Mass:Metastasis
from Nasopharyngeal Cancer An Unusual Presentation. Indian J PalliatCare. 2017 Jan-
Mar:23(1):i04-108. doi: 10.4103/0973-1075.19795 1. PubMed PMID:28216872: PubMed
Central PMCID: PMC5294429.

65. Noronha V. Patil VM, Joshi A, Chougule A. Banavali S. Prabhash K. Potential role of
metronomic chemotherapy in the treatment of esophageal andgastroesophageal cancer. Cancer
Lett. 2017 Aug 1:400:267-275. doi:10.1016/j.canlet.2017.01.017. Epub 2017 Jan 18. Review.
PubMed PMID: 28109908.
66. A. Joshi A, Noronha V, Patil VM, Kothari R. Sahu A. Kannan
Ramaswamy RA.Sable N.
Popat P, Menon S, Prabhash K. Patterns of Care and Clinical Outcomes in Patients With
Metastatic Renal Cell Carcinoma-Results From a Tertiary CancerCenter in India. Clin
Genitourin Cancer. 2017 Jun;15(3):e345-e355. doi: 10.1016/j.clgc.2016.09.006. Epub 2016 Oct
19. PubMed PMID: 28077238.

67. Patil VM, Noronha V, Joshi A, Zanwar S, Ramaswamy A, Arya S, Mahajan A.Bhattacharjee
A, Prabhash K. Dihydropyrimidine dehydrogenase mutation inneoadjuvant chemotherapy in
head and neck cancers: Myth or reality? South Asian JCancer. 2016 Oct-Dec:5(4): 182-185.
doi: 10.4103/2278-330X.195338. PubMed PMID:28032083: PubMed Central PMCID:
PMC5184753.

68. Pantziarka P, Hutchinson L, André N, Benzekry S. Bertolini F. Bhattacharjee A. Chiplunkar S.

Duda DG. Gota V, Gupta S, Joshi A, Kannan S, Kerbel R. Kieran M.Palazzo A. Parikh A.
Pasquier E, Patil V, Prabhash K. Shaked Y. Sholler GS.Sterba J. Waxman DI. Banavali S.
Next generation metronomic chemotherapy-reportfrom the Fifth Biennial International
Metronomic and Anti-angiogenic TherapyMeeting. 6-8 May 2016. Mumbai.
Ecancermedicalscience. 2016 Nov 2:10:689.eCollection 2016. PubMed PMID: 27994645
PubMed Central PMCID: PMC5130328.

69. Patil V, Joshi A, Noronha V, Deodhar J. Bhattacharjee A. Dhumal S.Chandrakanth MV. Karpe
A, Talreja V, Chandrasekharan A. Turkar S. Ramaswamy A.Prabhash K. Expectations and
preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncol. 2016
Dec:63:10-15. doi:10.1016/j.oraloncology.2016.10.023. Epub 2016 Nov 4. PubMed PMID:
27938994.

70. Byregowda S, Prabhash K. Puri A. Joshi A. Noronha V. Patil VM. Panda PK.Gulia A
J Palliat Care.
Aggressive Surgery in Palliative Setting of Lung Cancer: Is it Helpful? Indian
2016 Oct-Dec:22(4):504-506. PubMed PMID: 27803575: PubMed Central PMCID:
PMC5072245.

71. Noronha V, Joshi A, Muddu VK. Maruti Patil V., Prabhash K. Cabazitaxel forMetastatic
Castration-Resistant Prostate Cancer: Retrospective Data Analysis froman Indian Centre. Case

Rep Oncol. 2016 Aug 30:9(2):506-515. eCollection 2016May-Aug. PubMed PMID:

27721776:; PubMed Central PMCID: PMC5043265.
Kane S. Kumar R, SahuA, Doshi
72. Noronha V, Ramaswamy A, Patil VM, Joshi A, Chougule A.
V, Nayak L, Mahajan A, Janu A, Prabhash
K. ALK Positive Lung Cancer:Clinical Profile.
One. 2016Sep 16;11(9):e0160752. doi:
Practice and Outcomes in a Developing Country. PLoS
PLoS One. 2016 Dec 9:1|(12
10.1371/journal.pone.0160752. eCollection 2016.Erratum in:
:e0168221. PubMed PMID: 27637025; PubMed Central PMCID: PMC5026380.

A, Prabhash K. Lung cancer in thelndian

73. Noronha V, Pinninti R, Patil VM. Joshi
doi:10.4103/2278-
subcontinent. South Asian J Cancer. 2016 Jul-Sep:5(3):95-103.
330X.187571. Review. PubMed PMID: 27606290; PubMed Central PMCID:PMC4991146.

PET/CT in Differentiated Thyroid CarcinomaWith

74. Basu S, Joshi A. 68Ga DOTATATE
Sorafenib. Clin Nucl Med. 2016Oct:41(10):772-3.
Fibular Metastasis and Mixed Response to
PubMed PMID: 27500511.
doi: 10.1097/RLU.0000000000001327.
75. Patil VM. Noronha V, Joshi A, Banavali SD. Muddu V. Prabhash K.
PreoperativeChemotherapy and Metronomic Scheduling of Chemotherapy in Locally
Advanced OralCancers. Oncology. 2016:91 Suppl 1:35-40. doi: 10.1159/000447579. Epub
2016 JulReview. PubMed PMID: 27463093.

76. Noronha V, Sahu A. Patil VM, Joshi A, Ramaswamy A. Chandrasekharan A. Kadam N.

Prabhash K. Weekly paclitaxel as metronomic palliative chemotherapy in smallcell lung
cancer. South Asian J Cancer. 2016 Apr-Jun;5(2):67-9. doi:10.4103/2278-33OX.181643.
PubMed PMID: 27275452: PubMed Central PMCID:PMC4873701.

77. Patil VM, Noronh V., Joshi A. Karpe A. Talreja V, Chandrasekharan A. DhumalS. Prabhash K.
Metronomic palliative chemotherapy in maxillary sinus tumor. SouthAsian J Cancer. 20166
Apr-Jun;5(2):56-8. doi: 10.4103/2278-330X. 181626. PubMedPMID: 27275447: PubMed
Central PMCID: PMC4873696.

78. Noronha V, Joshi A, Patil VM, Purandare N, Jiwnani S. Ghosh-Laskar S. Nakti D. Bandekar
B, Prabhash K. Efficacy and Safety of Induction Chemotherapy inEsophageal Cancer with
Airway Involvement. J Gastrointest Cancer. 2016Sep:47(3):294-304. doi: 10. 1007/s1 2029.
016-9830-8. PubMed PMID: 27198523.

79. Joshi A, Patil VM, Noronha V, Ghosh J. Bhattacharjee A. Prabhash K. Across-sectional

observation study regarding patients and their physicianwillingness to wait for driver mutation
report in nonsmall-cell lung cancer.Indian J Med Paediatr Oncol. 2016 Apr-Jun:37(2):74-8.
doi:10.4103/0971-5851.180138. PubMed PMID: 27168703: PubMed Central
PMCID:PMC4854050.

80. Noronha V, Punatar S, Joshi A. Desphande RV. Prabhash K. Sunitinib-inducedthrombotie

microangiopathy. J Cancer Res Ther. 2016 Jan-Mar:120):6-11. doi:10.4103/0973
1482.172575. Review. PubMed PMID: 27072203.

81. Noronha V, Prabhash K, Joshi A, Patil VM, Talole S. Nakti D. Sahu A. Shah S.Ghosh-Laskar
S, Patil PS, Mehta SA, Jambhekar N. Mahajan A. Purandare N. ClinicalOutcome in Definitive
Concurrent Chemoradiation With Weekly Paclitasel andCarboplatin for Locally Advanced
Esophageal and Junctional Cancer. Oncol Res.2016:23(4):183-95. doi:
10.3727/096504016X14537290676865. PubMed PMID: 27053347.

82. Patil VM, Joshi A. Noronha V, Karpe A, Ramaswamy A. Dhumal S. Juvekar S.Arya S.
Mahajan A, Chaturvedi P, Pai P, D'Cruz A. Prabhash K. Technicallyunresectable recurrent oral
cancers: I s NACT the answer? Oral Oncol. 2016May:56:e12-4. doi:
10.1016/.oraloncology.2016.03.015. Epub 2016 Mar 31. PubMedPMID: 27050928.

83. Noronha V, Joshi A, Patil VM, JandyalS. Mittal N. Purandare N. Agarwal J.Kadam N
Prabhash K. Curative intent therapy in oligometastatic lung cancer with an unresectable
primary with N3 nodes: case report and review of the literature. Lung Cancer Manag. 2016
Apr:5(1):21-27. doi: 10.2217/mt-2016-0002. Epub 2016 Apr8. PubMed PMID: 30643546:
PubMed Central PMCID: PMC6310324.

84. Noronha V. Ostwal V. Ramaswamy A. Joshi A. Nair R. Banavali SD. Prabhash K. Chicken
pox infection in patients undergoing chemotherapy: A retrospectiveanaly sis from a tertiary
 care center in India. JInfect Public Heath. 2017 Jan Feb:10():8-13. doi
10.1016/jiph.2015.12.016. Epub 2016 Mar 9. PubMed PMID:26970699.
85. Patil VM, Joshi A, Noronha V, Sharma V, Zanwar S. Dhumal s. Kane S. Pai P.D'Cruz A.
Chaturvedi P, Bhattacharjee A, Prabhash K. Neoadjuvant Chemotherapy in Locally Advanced
and Borderline Resectable Nonsquamous Sinonasal Tumors(Esthesioneuroblastoma and
Sinonasal Tumor with Neuroendocrine Differentiation). Int J Surg Oncol. 2016:2016:6923730.
doi: 10.1155/2016/6923730. Epub 2016 Feb 3. PubMed PMID: 26955484: PubMed Central
PMCID: PMC4756189.

86. Joshi A, Noronha V, Sharma M. Dhumal S. Juvekar S. Patil VM. Pai P. Prabhashk.
Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma withintracranial
extension: Report of two cases with literature review. J Cancer Res Ther. 2015 Oct-
Dec;11(4):1003-5. doi: 10.4103/0973-1482.165878. PubMed PMID:26881569.

87. Joshi A, Tandon N, Noronha V. Dhumal S. Patil V. Arya S. Juvekar S. Agarwal J. DCruz A.
Pai P, Prabhash K. Neoadjuvant chemotherapy in technicallyunresectable carcinoma of
external auditory canal. Indian J Med Paediatr Oncol.2015 Jul-Sep:36(3):172-5. doi:
10.4103/0971-5851.166734. PubMed PMID: 26855526:PubMed Central PMCID:
PMC4743187.

88. Patil VM, Noronha V, Joshi A. Pinninti R. Dhumal S. Bhattacharjee A.Prabhash K.

Metronomic chemotherapy n platinum-insensitive failures and or early failures
postmultimodality management in oral eancers. Indian Med PaediatrOncol. 2015 Jul
Sep:36(3): 161-5. doi: 10.4103/0971-5851.166725. PubMed PMID:26855524; PubMed Central
PMCID: PMC4743183.

89. Naronha V, Pinninti R, Joshi A, Prabhash K. Renal impairment in prostatecancer: A close look
is important. Indian J Cancer. 2015 Jan-Mar:52(1):113. doi: 10.4103 0019-509X. 175561
PubMed PMID: 26837995.

90. Joshi P, Joshi A, Prabhash K. Noronha V. Chaturvedi P. Comparison otpostoperative

complications in advanced head and neck cancer patients receivingneoadjuvant chemotherapy
followed by surgery versus surgery alone. Indian J MedPaediatr Oncol. 2015 Oct
Dec:36(4):249-54. doi: 10.4103/0971-5851.171548. PubMed PMID: 26811595: PubMed
Central PMCID: PMC4711224.

91. Pandey AV. Phillip DS. Noronha V, Joshi A. Janu A. Jambekar N, Kaushal R,Mahajan A
Prabhash K. Maintenance pemetrexed in nonsmall cell lung carcinoma:Outcome analysis from
a tertiary care center. Indian J Med Paediatr Oncol. 20150ct-Dec:36(4):23842. doi:
10.4103/0971-5851.171544. PubMed PMID: 26811593:PubMed Central PMCID:
PMC4711222.

92. Shetty N, Joshi A. Noronha V. Dhumal S. Epari S, Prabhash K, Patil V.Extra-lymphatic

filariasis at reconstructive surgery flap site recurrence of headand neck cancer. IDCases. 2015
Dec 8,3:8-9. doi: 10.1016j.idcr.2015.1.001.eCollection 2016. PubMed PMID: 26793481
PubMed Central PMCID: PMC4719799.
93. Bhat V, Joshi A, Sarode R, Chavan P.
Cytomegalovirus infection in the bonemarrow transplant
patient. World J Transplant. 2015 Dec 24:5(4):287-91. doi:10.5500/wjt.v5.i4.287. Review.
PubMed PMID: 26722656; PubMed Central PMCID:PMC4689939.

94. Prabhash K, Noronha V, Joshi A. Role of Pneumococcal Vaccination in

Oncology Patients.
Assoc Physicians India. 2015 Apr:63(4 Suppl):38-9. Review. PubMedPMID:
26562965.Murthy V, Masodkar R, Kalyani N, Mahantshetty U. Bakshi G. Prakash G. JoshiA.
Prabhash K, Ghonge S, Shrivastava S. Clinical Outcomes With Dose-EscalatedAdaptive
Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. Int JRadiat Oncol Biol
Phys. 2016 Jan 1:94(1):60-66. doi:10.1016j.ijrobp.2015.09.010. Epub 2015 Sep 16. PubMed
PMID: 26547385.

95. Sahu P, Patil VM, Joshi A. Noronha V. Dhumal S. Kane S. D'Cruz A. PrabhashK.
Neoadjuvant chemotherapy and surgical margin in technically unresectablebuccal mucosa
cancers. Oral Oncol. 2015 Dec:51(12):e91-2. doi:10.1016/j.oraloncology.2015.10.004. Epub
2015 Oct 29. PubMed PMID: 26520048.

96. Patil VM, Noronha V, Joshi A. Muddu V. Dhumal S. Bhattacharjee A. PrabhashK.

Compliance With Neoadjuvant Chemotherapy in T4 Oral Caneers: Place.
Person,Socioeconomic Status, or Assistance. J Glob Oncol. 2015 Oct 28:1(2):65-72.
doi:10.1200/JGO.2015.000265. eCollection 2015 Dec. PubMed PMID: 28804775;
PubMedCentral PMCID: PMC5539870.

97. Noronha V, Joshi A, Marfatia S. Patil V. Juvekar S. Arya S. Banavali S.Prabhash K. Health-
related quality of life in patients with metastatic. relapsed.or inoperable squamous cell
carcinoma ofthe head and neck in India. Support CareCancer. 2016 Apr:24(4):1 595-602. doi:
10.1007/s00520-015-2937-9. Epub 2015 Sep19. PubMed PMID: 26386707.

98. Noronha V, Joshi A, Patil V, Dhumal S. Agarwala V. Prabhash K. Excellentresponse to oral

Metronomic chemotherapy in unresectable adenocarcinoma ofexternal auditory canal. Indian J
Med Paediatr Oncol. 2015 Apr-Jun:36(2): 132.doi: 10.4103/0971-5851.158849. PubMed
PMID: 26157292; PubMed Central PMCID:PMC4477377.

99. Basu S, Dandekar M, Joshi A. D'Cruz A. Defining a rational step-carealgorithm for managing
thyroid carcinoma patients with elevated thyroglobulin andnegative on radioiodine
scintigraphy (TENIS): considerations and challengestowards developing an appropriate
roadmap. Eur J Nucl Med Mol Imaging. 2015Jul:42(8):| 167-71. doi: 10.1007/s00259-015
3058-x. Epub 2015 May 20. PubMed PMID:25989850.

100. Patil VM, Noronha V. Joshi A. Muddu VK. Dhumal S. BhosaleB. Arya S.
JuvekarBanavali S, D'Cruz A, Bhattacharjee A. Prabhash K. A prospective randomizedphase II
study comparing metronomie chemotherapy with chemotherapy (single agent cisplatin), in
patients with metastatic, relapsed or inoperable squamous cellcarcinoma of head and neck.
Oral Oncol. 2015 Mar:51(3):279-36. doi:10.1016/j.oraloncology.2014.12.002. Epub 2015 Jan
8. PubMed PMID: 25578869.